Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Janux Therapeutics is a clinical-stage biopharmaceutical company developing T cell engager (TCE) therapies using its proprietary Tumor Activated T Cell Engager (TRACTr) platform. The company's lead programs target solid tumors including prostate cancer (JANX007) and ovarian cancer (JANX008), with a pipeline focused on conditionally activated biologics designed to minimize systemic toxicity while maximizing tumor-specific immune responses. As a pre-revenue biotech with $0.8B market cap and strong balance sheet (35.86x current ratio), the stock trades on clinical trial readouts and partnership potential.
Janux operates a classic clinical-stage biotech model: burn cash to advance drug candidates through FDA trials (Phase 1/2 currently), seeking either regulatory approval for commercialization or lucrative partnership deals with large pharma. The TRACTr platform differentiates by using tumor microenvironment activation to reduce off-tumor toxicity - a critical advantage over traditional TCEs that have shown dose-limiting toxicities. Monetization paths include: (1) partnering programs pre-approval for upfront payments plus milestones/royalties, (2) commercializing independently post-approval in niche indications, or (3) acquisition by large pharma seeking differentiated oncology assets. Current cash runway estimated through 2027-2028 based on burn rate.
Clinical trial data readouts for JANX007 (PSMA-targeted prostate cancer) and JANX008 (EGFR-targeted ovarian cancer) - efficacy signals, safety profiles, and dose escalation milestones
Partnership announcements or licensing deals with large pharmaceutical companies for platform technology or specific programs
FDA regulatory interactions including IND clearances for new programs, Fast Track designations, or breakthrough therapy designations
Cash runway updates and financing events (equity raises, dilution concerns given negative cash flow)
Competitive clinical data from rival TCE platforms (Amgen, Regeneron, AbbVie) that validate or challenge the TRACTr approach
Broader biotech sector sentiment and risk appetite for clinical-stage assets
Binary clinical trial risk - single negative Phase 2 readout can eliminate 50-80% of market value overnight, as seen across biotech sector. JANX007/JANX008 data quality determines viability.
Regulatory pathway uncertainty for novel TCE mechanisms - FDA may require larger safety databases or longer follow-up than anticipated, extending timelines and cash needs beyond runway
Competitive intensity in T cell engager space with well-funded rivals (Amgen's BiTE platform, Regeneron, J&J) potentially reaching market first or demonstrating superior profiles
Large pharma TCE programs with greater resources and established oncology commercialization infrastructure could capture market share even with similar efficacy profiles
Alternative immunotherapy modalities (CAR-T, ADCs, checkpoint inhibitors) continue advancing and may address same patient populations with better risk/benefit profiles
Platform technology risk - if TRACTr conditional activation does not demonstrate meaningful safety advantage over traditional TCEs in clinic, core differentiation thesis fails
Cash runway risk - with -$0.0B operating cash flow (approximately -$50-70M annual burn estimated), company will require additional financing before pivotal trial results, risking dilution at unfavorable valuations
Equity financing overhang - 54.5% decline in 3 months suggests potential near-term capital raise at depressed prices, diluting existing shareholders significantly
No debt cushion - while 0.02 D/E is healthy, lack of non-dilutive financing options means all capital needs met through equity, increasing dilution risk versus peers with venture debt access
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is committed multi-year investment independent of economic cycles. However, financing conditions and investor risk appetite for speculative growth assets are highly cyclical, affecting ability to raise capital and stock valuation multiples. Patient enrollment in trials continues regardless of economic conditions.
High sensitivity through valuation channel. As a pre-revenue asset with cash flows 5-10+ years out, Janux is valued on discounted future earnings. Rising rates increase discount rates applied to distant cash flows, compressing valuations significantly (evidenced by -64.4% 1-year return during 2024-2025 rate environment). Higher rates also increase opportunity cost of holding cash-burning growth stocks versus bonds. Financing costs are minimal given negligible debt (0.02 D/E), but equity financing becomes more expensive as cost of capital rises.
Minimal direct credit exposure given negligible debt and strong liquidity position. However, tighter credit conditions in biotech financing markets affect ability to raise growth capital through convertible debt or venture debt facilities. Broader credit stress can shut down IPO/follow-on markets, forcing dilutive financings or partnership deals on unfavorable terms.
growth - Pure speculative growth play attracting biotech specialists, venture-style investors, and momentum traders seeking multi-bagger returns from clinical success. Not suitable for value or income investors given no earnings, no dividends, and binary risk profile. Typical holders include biotech-focused hedge funds, venture capital crossover funds, and retail investors with high risk tolerance. 64.4% drawdown indicates this attracts risk-seeking capital willing to endure extreme volatility for asymmetric upside potential.
high - Clinical-stage biotech exhibits extreme volatility with 50%+ intraday moves common around data readouts. 54.5% quarterly decline demonstrates sensitivity to sentiment shifts, financing concerns, and competitive developments. Implied volatility typically 80-120% around catalyst events. Beta likely 1.5-2.5x relative to broader biotech indices given small-cap, single-asset risk concentration.
